164 related articles for article (PubMed ID: 26638758)
1. Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy.
Das SK; Wang W; Zhabyeyev P; Basu R; McLean B; Fan D; Parajuli N; DesAulniers J; Patel VB; Hajjar RJ; Dyck JR; Kassiri Z; Oudit GY
Sci Rep; 2015 Dec; 5():18132. PubMed ID: 26638758
[TBL] [Abstract][Full Text] [Related]
2. Prooxidant mechanisms in iron overload cardiomyopathy.
Cheng CF; Lian WS
Biomed Res Int; 2013; 2013():740573. PubMed ID: 24350287
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol enhanced FOXO3 phosphorylation via synergetic activation of SIRT1 and PI3K/Akt signaling to improve the effects of exercise in elderly rat hearts.
Lin CH; Lin CC; Ting WJ; Pai PY; Kuo CH; Ho TJ; Kuo WW; Chang CH; Huang CY; Lin WT
Age (Dordr); 2014; 36(5):9705. PubMed ID: 25158994
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis inhibitor improves cardiac function more effectively than inhibitors of apoptosis and necroptosis through cardiac mitochondrial protection in rats with iron-overloaded cardiomyopathy.
Kumfu S; Sripetchwandee J; Thonusin C; Sumneang N; Maneechote C; Arunsak B; Chunchai T; Oo TT; Kongkaew A; Chattipakorn SC; Chattipakorn N
Toxicol Appl Pharmacol; 2023 Nov; 479():116727. PubMed ID: 37863361
[TBL] [Abstract][Full Text] [Related]
5. d-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded rats.
Kramer JH; Spurney CF; Iantorno M; Tziros C; Chmielinska JJ; Mak IT; Weglicki WB
Can J Physiol Pharmacol; 2012 Sep; 90(9):1257-68. PubMed ID: 22913465
[TBL] [Abstract][Full Text] [Related]
6. Niacin treatment prevents bone loss in iron overload osteoporotic rats via activation of SIRT1 signaling pathway.
Tao Z; Tao M; Zhou M; Wu XJ
Chem Biol Interact; 2024 Jan; 388():110827. PubMed ID: 38081572
[TBL] [Abstract][Full Text] [Related]
7. Duality of Nrf2 in iron-overload cardiomyopathy.
Federti E; Vinchi F; Iatcenko I; Ghigo A; Matte A; Toya SCM; Siciliano A; Chiabrando D; Tolosano E; Vance SZ; Riccardi V; Andolfo I; Iezzi M; Lamolinara A; Iolascon A; De Franceschi L
Haematologica; 2023 May; 108(5):1335-1348. PubMed ID: 36700398
[TBL] [Abstract][Full Text] [Related]
8. Iron overload cardiomyopathy: better understanding of an increasing disorder.
Gujja P; Rosing DR; Tripodi DJ; Shizukuda Y
J Am Coll Cardiol; 2010 Sep; 56(13):1001-12. PubMed ID: 20846597
[TBL] [Abstract][Full Text] [Related]
9. More Than Meets the Eye: Defining the Prevalence, Pathophysiology, and Approach to Myocardial Iron Overload.
Truby LK; Michelis K; Grodin JL
Am J Cardiol; 2024 May; 219():38-43. PubMed ID: 38461925
[No Abstract] [Full Text] [Related]
10. Perturbations in lipid metabolism and gut microbiota composition precede cardiac dysfunction in a mouse model of thalassemia.
Liu Y; Fillebeen C; Forest A; Botta A; Varin TV; Marette A; Burelle Y; Des Rosiers C; Pantopoulos K; Sweeney G
FASEB J; 2023 Dec; 37(12):e23257. PubMed ID: 37902616
[TBL] [Abstract][Full Text] [Related]
11. Iron overload in diabetic retinopathy: a cause or a consequence of impaired mechanisms?
Ciudin A; Hernández C; Simó R
Exp Diabetes Res; 2010; 2010():. PubMed ID: 20827392
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical Effect of Caloric Restriction on Overload-Induced Muscle Growth in Diastolic Heart Failure.
Zádor E
JACC Basic Transl Sci; 2024 Feb; 9(2):241-243. PubMed ID: 38510718
[TBL] [Abstract][Full Text] [Related]
13. Females Are Protected From Iron-Overload Cardiomyopathy Independent of Iron Metabolism: Key Role of Oxidative Stress.
Das SK; Patel VB; Basu R; Wang W; DesAulniers J; Kassiri Z; Oudit GY
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28115312
[TBL] [Abstract][Full Text] [Related]
14. Advanced iron-overload cardiomyopathy in a genetic murine model is rescued by resveratrol therapy.
Das SK; Zhabyeyev P; Basu R; Patel VB; Dyck JRB; Kassiri Z; Oudit GY
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29208771
[TBL] [Abstract][Full Text] [Related]
15. TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease.
Zhabyeyev P; Das SK; Basu R; Shen M; Patel VB; Kassiri Z; Oudit GY
Am J Physiol Heart Circ Physiol; 2018 May; 314(5):H978-H990. PubMed ID: 29373036
[TBL] [Abstract][Full Text] [Related]
16. Imaging of the heart: historical perspective and recent advances.
Lam WC; Pennell DJ
Postgrad Med J; 2016 Feb; 92(1084):99-104. PubMed ID: 26647305
[TBL] [Abstract][Full Text] [Related]
17. Modulation of hepcidin to treat iron deregulation: potential clinical applications.
Blanchette NL; Manz DH; Torti FM; Torti SV
Expert Rev Hematol; 2016; 9(2):169-86. PubMed ID: 26669208
[TBL] [Abstract][Full Text] [Related]
18. The Molecular Mechanisms of Iron Metabolism and Its Role in Cardiac Dysfunction and Cardioprotection.
Ravingerová T; Kindernay L; Barteková M; Ferko M; Adameová A; Zohdi V; Bernátová I; Ferenczyová K; Lazou A
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114290
[TBL] [Abstract][Full Text] [Related]
19. Role of iron metabolism in heart failure: From iron deficiency to iron overload.
Zhang H; Zhabyeyev P; Wang S; Oudit GY
Biochim Biophys Acta Mol Basis Dis; 2019 Jul; 1865(7):1925-1937. PubMed ID: 31109456
[TBL] [Abstract][Full Text] [Related]
20. Research advances on molecular mechanism and natural product therapy of iron metabolism in heart failure.
Zhang T; Luo L; He Q; Xiao S; Li Y; Chen J; Qin T; Xiao Z; Ge Q
Eur J Med Res; 2024 Apr; 29(1):253. PubMed ID: 38659000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
